HER2/neu-directed therapy for biliary tract cancer

被引：0
|
作者：
Milind Javle
Chaitanya Churi
HyunSeon C. Kang
Rachna Shroff
Filip Janku
Rakesh Surapaneni
Mingxin Zuo
Christian Barrera
Humaid Alshamsi
Sunil Krishnan
Lopa Mishra
Robert A. Wolff
Ahmed O. Kaseb
Melanie B. Thomas
Abby B. Siegel
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine
[2] The University of Texas MD Anderson Cancer Center,Department of Diagnostic Radiology, Division of Diagnostic Imaging
[3] The University of Texas MD Anderson Cancer Center,Department of Investigational Cancer Therapeutics, Division of Cancer Medicine
[4] Scott & White Clinic,Department of Radiation Oncology, Division of Radiation Oncology
[5] The University of Texas MD Anderson Cancer Center,Department of Gastroenterology
[6] The University of Texas MD Anderson Cancer Center,Departments of Medicine and Surgery
[7] Gibbs Cancer Center & Research Institute,undefined
[8] Columbia University,undefined
来源：
Journal of Hematology & Oncology | / 8卷
关键词：
Receptor; ErbB-2; Gallbladder neoplasms; Cancer of the biliary tract;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] HER2/neu-directed therapy for biliary tract cancer
    Javle, Milind
    Churi, Chaitanya
    Kang, HyunSeon C.
    Shroff, Rachna
    Janku, Filip
    Surapaneni, Rakesh
    Zuo, Mingxin
    Barrera, Christian
    Alshamsi, Humaid
    Krishnan, Sunil
    Mishra, Lopa
    Wolff, Robert A.
    Kaseb, Ahmed O.
    Thomas, Melanie B.
    Siegel, Abby B.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [2] Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene
    Harbeck, Nadia
    Pegram, Mark D.
    Rueschoff, Josef
    Moebus, Volker
    BREAST CARE, 2010, 5 : 3 - 7
  • [3] HER2 Directed Therapy for Gastric/Esophageal Cancers
    Won, Elizabeth
    Janjigian, Yelena J.
    Ilson, David H.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (03) : 395 - 404
  • [4] Expression of Her2/neu in locally advanced bladder cancer:: Implication for a molecular targeted therapy
    Wülfing, C
    von Struensee, D
    Bierer, S
    Bögemann, M
    Hertle, L
    Eltze, E
    AKTUELLE UROLOGIE, 2005, 36 (05) : 423 - 429
  • [5] 'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer
    Santini, D.
    Vincenzi, B.
    Pantano, F.
    Schiavon, G.
    Tonini, G.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1715 - 1717
  • [6] Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors
    Hardee, Matthew E.
    Eapen, Rose J.
    Rabbani, Zahid N.
    Dreher, Matthew R.
    Marks, Jeffrey
    Blackwell, Kimberly L.
    Dewhirst, Mark W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 219 - 228
  • [7] HER2/neu testing in primary colorectal carcinoma
    Heppner, B. Ingold
    Behrens, H-M
    Balschun, K.
    Haag, J.
    Krueger, S.
    Becker, T.
    Roecken, C.
    BRITISH JOURNAL OF CANCER, 2014, 111 (10) : 1977 - 1984
  • [8] The role of HER2 in cancer therapy and targeted drug delivery
    Tai, Wanyi
    Mahato, Rubi
    Cheng, Kun
    JOURNAL OF CONTROLLED RELEASE, 2010, 146 (03) : 264 - 275
  • [9] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [10] Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer
    Gullo, Giuseppe
    Bettio, Daniela
    Torri, Valter
    Masci, Giovanna
    Salvini, Piermario
    Santoro, Armando
    INVESTIGATIONAL NEW DRUGS, 2009, 27 (02) : 179 - 183
12345